Sam Fazeli discusses Eli Lilly acquiring Morphic. Sean O'Hara talks about the ETF market. Jared Dillian advises investors. The show covers pharmaceutical acquisitions, market stability, green hydrogen, and investment strategies.
Eli Lilly diversifies into immunology with Morphic acquisition to address inflammatory diseases.
Market insights stress importance of balancing confidence and caution in investments amidst market dynamics.
Deep dives
Current Trends in Trading Platforms by Schwab Trading and Ameritrade
Schwab Trading, now powered by Ameritrade, offers a new comprehensive trading experience tailored for traders, featuring thinkorswim, a powerful award-winning trading platform. Traders can benefit from the support of a dedicated Trade Desk team for trading assistance and access an extensive library of online education resources designed to enhance trading skills, creating a robust trading environment.
Strategic Acquisition of Morphic by Eli Lilly Expands Immunology Franchise
Eli Lilly's acquisition of Morphic aims to bolster its immunology franchise, focusing on addressing inflammatory diseases like arthritis, psoriasis, Crohn's disease, and inflammatory bowel disease. The deal aligns with Lilly's commitment to diversify beyond its GLP-1 business in areas of high unmet medical need, showing a strategic shift towards expanding therapeutic offerings.
Pharmaceutical M&A Strategies and Market Insights by Sam Fazelli
Sam Fazelli discusses pharmaceutical companies' M&A strategies, highlighting Lilly's acquisitions trend in diverse therapeutic areas. With a focus on enhancing pipelines and exploring strategic deals, pharmaceutical companies like Lilly allocate significant proportions of their pipelines to M&A activities, aiming to strengthen their product portfolios and drive growth.
Market Analysis and Investment Strategies by Shelby McFadden from Motley Fool Asset Management
Shelby McFadden delves into market insights, addressing concerns around market concentration and valuation risks, particularly focusing on the balance between confidence and caution in market investments. Evaluating market breadth and investment opportunities across asset classes, McFadden emphasizes the importance of maintaining a balanced investment approach amidst evolving market dynamics.
On today's podcast: Sam Fazeli, Bloomberg Intelligence Director of Research for Global Industries and Senior Pharmaceuticals, on Eli Lilly agreeing to buy Biotech company Morphic. Shelby McFaddin, Investment Analyst at Motley Fool Asset Management. Sean O'Hara, President of Pacer ETFs, on current state of ETFs. Jared Dillian, author and Founder of The Daily Dirtnap, on what investors should be looking out for. And Martin Tengler, Bloomberg BNEF Head of Hydrogen, on US climate goals using clean hydrogen